Methods of Determining the Prognosis of an Adenocarcinoma
Posted Sep 30 2008 5:00pm
Description of Invention: Available for licensing and commercial development is a novel method for determining the prognosis of a subject with adenocarcinoma in an organ, such as the lung, and to aid in the selection of a specific therapeutic regimen. Lung adenocarcinoma (AC) is the predominant histological subtype of lung cancer, which is the leading cause of cancer deaths worldwide. The risk of metastasis remains substantial in AC patients, even when a curative resection of early-stage AC is performed. The prognosis includes the determination of the likelihood of survival, the likelihood of metastasis, or both. The method includes quantization of the expression of a plurality of Th1 and Th2 cytokines of interest in the adenocarcinoma and in non-cancerous tissue in the organ. Altered expression of one or more of the Th1 and Th2 cytokines in the adenocarcinoma as compared to the non-cancerous tissue determines the prognosis for the subject. The method is capable of distinguishing patients with lymph node metastasis versus those with short term survival. Furthermore, methods are provided for evaluating the effectiveness of anti-cancer agents.
Applications: Prognosis of adenocarcinoma, aid in the selection of specific therapeutic regimens and evaluation of the effectiveness of anti-cancer agents.
Development Status: The technology is in early stage of development.
Patent Status: HHS, Reference No. E-263-2006/1 PCT, Application No. PCT/US2007/073637 filed 16 Jul 2007 (published as WO 2008/009028 on 17 Jan 2008; claiming priority to 14 Jul 2006) US, Application No. 12/373,191 filed 09 Jan 2009
Licensing Status: Available for non-exclusive or exclusive licensing.
Portfolios: Devices/Instrumentation Devices/Instrumentation - Diagnostics Cancer Cancer - Diagnostics Rare Diseases
For Additional Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4633 Fax: 301-402-0220